Boca Grove Adds Pickleball Courts

BOCA RATON, Fla., June 23, 2017 /PRNewswire/ -- Boca Grove Golf and Tennis Club, a premier country club in Boca Raton, Fla., has added two new pickleball courts to our tennis facilities. The two new courts join the already existing red-clay stadium court and 12 Har-Tru clay tennis courts. Pickleball combines elements of tennis, badminton and ping-pong, and is easily played by all ages. 

After Boca Grove hosted a pickleball demonstration event last year, the new sports addiction caught on quickly at the Club and a need for official courts became a priority. Both current and former tennis enthusiasts are finding pickleball's smaller courts and similar style of play very appealing and younger players especially are enjoying the change of pace. Pickleball can be played as singles or doubles and is played with a paddle and plastic balls with holes.

"The new pickleball courts are attracting members we don't normally see at the Tennis Center, as they are taking an interest in the new sport available at Boca Grove. We have also found that the game of pickleball is infusing a new spirit of camaraderie across all groups with senior and younger members joining forces and playing together. The courts have also added a distinct advantage to our junior tennis lessons. The smaller courts are allowing the younger players to grow confidence and knowledge of the game of tennis on courts relative to their size," said Richard Centerbar, Director of Tennis at Boca Grove.

Boca Grove's tennis courts have hosted numerous tennis professionals, including Andy Murray, Ivan Lendl, Grigor Dimitrov, and Kevin Anderson.

About Boca Grove:
Boca Grove is a boutique golf and tennis club located in the heart of beautiful Boca Raton, Florida. With approximately 444 member families, Boca Grove exhibits style and grace afforded only to the most elite private clubs in South Florida. For more information on Boca Grove Golf and Tennis Club, please visit www.bocagrove.org  or call (561)487-5300.

Media Contact:
Heather Dupree
561.837.4800 ext. 133
hdupree@bocagrove.org

SOURCE Boca Grove Golf and Tennis Club

Silicon Valley Companies Join Together to Raise Money for The Leukemia & Lymphoma Society

CBRE earns title of 2017 Silicon Valley Kickball Classic Champions

SAN JOSE, Calif., June 23, 2017 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society's (LLS) Silicon Valley & Monterey Bay Area Chapter hosted its 2nd Annual Silicon Valley Kickball Classic in Sunnyvale at Twin Creeks Sports Complex on June 8, 2017. Silicon Valley companies came out to fight for the title of Kickball Classic Champions, and more importantly, to join the fight against cancer by contributing over $80,000.

The Silicon Valley Kickball Classic is a corporate event where companies signup as a team to compete in the tournament. In addition to playing kickball, there are additional perks such as a beer garden, DJ, and yard games all designed for a fun and engaging day.  The Kickball Classic is a great opportunity for companies to engage in corporate social responsibility while also promoting networking, teambuilding, and strengthening relationships with co-workers outside of the office.

This year was especially inspiring due to the incredible support of the Silicon Valley corporate community. Teams included Adobe, CBRE, CLUBWAKA, GlobalLogic, Hyatt Regency Santa Clara, Lexus Stevens Creek, Mercedes-Benz Research & Development North America, San Jose Earthquakes, SignalFire, Signifyd, Silicon Valley Bank, Twistlock, and Vanguard Software Corporation. After a day of fierce, friendly competition, CBRE won the title of, "2017 Silicon Valley Kickball Classic Champions".

Returning as Founding and Presenting Sponsor was Silicon Valley Bank (SVB). Through LLS's long-standing partnership with SVB, together both organizations have been able to create a unique event that continues to engage the corporate community and encourages charitable giving.  

"The LLS Kickball Classic is a fantastic opportunity for companies, including SVB'ers to come together outside of work while supporting a great cause and giving back to the community. SVB is extremely proud to be a part of such an amazing event!" said Chase Clymer, Associate at Silicon Valley Bank.

"We are thankful to be a part of a community where so many companies see the value in supporting causes like The Leukemia & Lymphoma Society. With the support of these corporations, LLS can continue to invest in research that is making a significant impact in the fight against cancer" said Courtney Karnes, Executive Director of the Silicon Valley & Monterey Bay Area Chapter.  

LLS is the world's leading non-profit voluntary health organization dedicated to finding cures for blood cancers and ensuring that patients have access to lifesaving treatments. Through events like the Silicon Valley Kickball Classic, LLS has invested more than $1 billion in research to advance breakthrough therapies. The funds raised are used for:

  • Research to advance targeted therapies and immunotherapies that are saving thousands of lives
  • Blood cancer information, education and support for patients
  • Policies that ensure patients have access to blood cancer treatments

The Silicon Valley Kickball Classic was captured by Rook Productions Media and a glimpse into the day can be seen here: video.

To learn more about the Silicon Valley Kickball Classic visit: bit.ly/svkickballclassic

For additional ways to support The Leukemia & Lymphoma Society in the Silicon Valley & Monterey Area visit: https://www.lls.org/silicon-valley-monterey-bay-area

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in Rye Brook, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org.

SOURCE The Leukemia & Lymphoma Society's (LLS) Silicon Valley & Monterey Bay Area Chapter

Quirónsalud Introduces the First Mobile Hospital of MotoGP World Cup to Improve the Health Protection of Pilots in European Circuits

MADRID, June 23, 2017 /PRNewswire/ --

Quirónsalud extends its collaboration with MotoGP World Cup introducing the first mobile hospital in the circuit. Another step in formalising the support Quirónsalud has been lending to MotoGP World Cup since 2013 through the professional first responder team who operates on the track with medical vehicles.

     (Photo: http://mma.prnewswire.com/media/527133/Quironsalud_MotoGP_World_Cup.jpg )

The new unit, under the medical direction of Dr. Ángel Charte, will be equipped with digital radiology, soft and abdominal ultrasound scanner, electrocardiogram with monitor and resuscitation unit, among other equipment. This new mobile hospital will be present in the 12 European circuits since 2018, in order to increase the safety of the pilots in the race from any unforeseen events.

"Quirónsalud provides to MotoGP World Cup competition all our health experience to strengthen the safety of pilots in the circuit," says Julio Fernández-Llamazares, Corporate Director of Communications and External Relations of Quirónsalud. "In addition, we reaffirm our commitment to continue to promote healthy living habits, in which sports practice stands out for its recognized health benefits," he adds.

Pau Serranta, General Director of the Commercial Area of Dorna Sports, states: "We are pleased that we have signed the agreement with Quirónsalud, creating closer ties between us with the sponsorship of Clinica Mobile, which is a reference in Moto GP World Cup."

For his part, Dr. Angel Charte highlights that he is "proud of this partnership because it brings the highest standards of medical care to the motoring world in such sensitive and important specialties in MotoGP as intensive care medicine and severe polytrauma and patients."

This arrangement reinforces Quirónsalud position of avant-garde and innovation in the main medical specialties and, in particular, in sports medicine, that will be the main protagonist of its future hospital, as part of the Caleido project, at the Castellana's 'Fifth Tower' in Madrid.

About Quirónsalud 

Quirónsalud is the most important hospital group in Spain and the third in Europe. It has presence in 13 autonomous communities, holding the most advanced technology and offering more than 6,200 beds in more than 80 centers. Quirónsalud is pioneer in different specialties such as cardiology, endocrinology, gynecology, neurology, oncology and sports medicine, among others.  

Contact:  Natalia Gutierrez; ngutierrez@tinkle.es , Begoña Moreno; bmoreno@tinkle.es, +44-917021010


Quirónsalud Introduces the First Mobile Hospital of MotoGP World Cup to Improve the Health Protection of Pilots in European Circuits

MADRID, June 23, 2017 /PRNewswire/ --

Quirónsalud extends its collaboration with MotoGP World Cup introducing the first mobile hospital in the circuit. Another step in formalising the support Quirónsalud has been lending to MotoGP World Cup since 2013 through the professional first responder team who operates on the track with medical vehicles.

     (Photo: http://mma.prnewswire.com/media/527133/Quironsalud_MotoGP_World_Cup.jpg )

The new unit, under the medical direction of Dr. Ángel Charte, will be equipped with digital radiology, soft and abdominal ultrasound scanner, electrocardiogram with monitor and resuscitation unit, among other equipment. This new mobile hospital will be present in the 12 European circuits since 2018, in order to increase the safety of the pilots in the race from any unforeseen events.

"Quirónsalud provides to MotoGP World Cup competition all our health experience to strengthen the safety of pilots in the circuit," says Julio Fernández-Llamazares, Corporate Director of Communications and External Relations of Quirónsalud. "In addition, we reaffirm our commitment to continue to promote healthy living habits, in which sports practice stands out for its recognized health benefits," he adds.

Pau Serranta, General Director of the Commercial Area of Dorna Sports, states: "We are pleased that we have signed the agreement with Quirónsalud, creating closer ties between us with the sponsorship of Clinica Mobile, which is a reference in Moto GP World Cup."

For his part, Dr. Angel Charte highlights that he is "proud of this partnership because it brings the highest standards of medical care to the motoring world in such sensitive and important specialties in MotoGP as intensive care medicine and severe polytrauma and patients."

This arrangement reinforces Quirónsalud position of avant-garde and innovation in the main medical specialties and, in particular, in sports medicine, that will be the main protagonist of its future hospital, as part of the Caleido project, at the Castellana's 'Fifth Tower' in Madrid.

About Quirónsalud 

Quirónsalud is the most important hospital group in Spain and the third in Europe. It has presence in 13 autonomous communities, holding the most advanced technology and offering more than 6,200 beds in more than 80 centers. Quirónsalud is pioneer in different specialties such as cardiology, endocrinology, gynecology, neurology, oncology and sports medicine, among others.  

Contact:  Natalia Gutierrez; ngutierrez@tinkle.es , Begoña Moreno; bmoreno@tinkle.es, +44-917021010


Linemark Announces Support of 10th Annual Paralyzed Veterans Golf Open

Critical event raises funds for PAVE program to support and address issue of veteran employment

LANSDOWNE, Va., June 23, 2017 /PRNewswire/ -- Linemark Printing, Inc. announced its support and sponsorship of the 10th annual Paralyzed Veterans Golf Open, a full day event that brings together veterans, their caregivers and families, business leaders, military and government officials. This is the 10th year that Linemark has supported the PVGO, a unique event that enables paralyzed veterans and disabled military members to play golf alongside professional athletes and other supporters and showcase the latest adaptive sports technology.

We would also like to congratulate David Ashton for being honored with the Phil Halcomb Patriot Award for service to our veterans and the event. "We are grateful for the service and sacrifice of our military and proud to be part of an event that makes a meaningful difference in the lives of our disabled veterans," said Ashton, EVP/Partner Linemark.

Since its inception in 2008, the PVGO has dedicated 100% of funds to Paralyzed Veterans of America's Paving Access for Veterans Employment (PAVE) program, which provides free, one-on-one career assistance, benefits counseling and support to any veteran or family member, as well as assistance to employers committed to hiring veterans.

This year's event is expected to raise more than $450K for PAVE, one of the fastest growing and most effective efforts to prepare and employ our nation's veterans. To date, the PVGO has raised $3.2M since its inaugural event in 2008, and more than 5,000 veterans and military caregivers have been positively impacted through the program's personalized training and assistance.

"We are honored to welcome Linemark as a sponsor of this year's PVGO, and grateful for its contributions and support," said Al Kovach, national president of Paralyzed Veterans of America. "We could not have continued to host the PVGO for the last ten years, and provide such meaningful care for veterans, their families and caregivers without the commitment of our sponsors."

The PAVE program provides free one-on-one career assistance, benefits counseling and support to all veterans, their families, and their caregivers. The program specializes in assisting disabled veterans seeking to re-enter the workforce. PAVE's masters-level certified vocational counselors placed one veteran, caregiver, or family member per day last year.  To learn more, visit http://www.pva.org/veterans-employment

About Paralyzed Veterans of America

Paralyzed Veterans of America is the only congressionally chartered veterans service organization dedicated solely for the benefit and representation of veterans with spinal cord injury or disease. For 70 years, Paralyzed Veterans has ensured that veterans have received the benefits earned through their service to our nation; monitored their care in VA spinal cord injury units; and funded research and education in the search for a cure and improved care for individuals with paralysis. As a partner for life, Paralyzed Veterans also develops training and career services, works to ensure accessibility in public buildings and spaces, provides health and rehabilitation opportunities through sports and recreation and advocates for veterans and all people with disabilities. With more than 70 offices and 34 chapters, Paralyzed Veterans serves veterans, their families and their caregivers in all 50 states, the District of Columbia and Puerto Rico. (pva.org)

About Linemark Printing Inc.

Linemark is an intensely customer focused company delivering robust & innovative communications solutions to a client base of associations, corporations, and non-profit organizations. The 90,000 sq. Ft. National headquarters is located within close proximity to the Washington DC / Baltimore Metro areas. As one of the leading and fastest growing communications companies in the country, Linemark has made their mark with best in class, technology driven, and measurable client results.

Contact: marketing@linemark.com, 301-925-9000

SOURCE Linemark

Winter Park: Center of Motorcycle Touring Universe

Colorado Motomarathon Set for Sept. 8-11

WINTER PARK, Colo., June 23, 2017 /PRNewswire/ -- Already established as Mountain Bike Capital USA™, Winter Park is also drawing attention as a national center for motorcycle touring.

"With spectacular mountain passes surrounding us on all sides, Winter Park is the perfect location for our long-distance sport-touring rides," said John Metzger, founder of the Motomarathon Association. "Grand County and the surrounding area is becoming a Mecca for motorcycling."

The Colorado Motomarathon is set for Sept. 8-11. For a $50 fee, participants receive precisely engineered routes for four days, averaging 300-400 miles per day.

Motomarathon routes are kept secret until the night before each day's ride. Participants complete a series of self-recorded checkpoints, photographing their badge numbers at designated landmarks. Each rider will receive a paperback copy of Metzger's new book, Meditation by Motorcycle – Riding Your Carbon Footprint to the Apex of Enlightenment. For further information and to register, visit www.motomarathon.com. Contact: John Metzger, John@Motomarathon.com, 303-641-1062.

 

SOURCE Motomarathon

Upper Deck Announces Release of First-Ever Digital Gaming App

Award-Winning Legendary® Deck Building Game Will Release This August, in Conjunction with Gen Con

CARLSBAD, Calif., June 23, 2017 /PRNewswire/ -- Upper Deck, an industry leader in trading cards, games and collectibles has announced today that it is launching a new digital gaming platform that will bring the company's top-selling games to mobile devices. The company has teamed up with SkyReacher Entertainment to create Legendary DXP™, the first-ever free to play App for Upper Deck's iconic Legendary game, in response to high demand from fans around the world.

Legendary DXP is a fantasy deck building game that brings the same great style of play that fans have enjoyed for years in a format that allows users to play wherever, whenever, and with whoever they want. The game is set in the fantastical world of Alamyth, where players recruit legendary heroes and fight terrifying forces of evil.  Players journey through the Firelands and other mythical worlds to fight the likes of Leprechaun Henchmen and dangerous evil villains.  While players fight to the end collecting victory points for the win, the Mastermind 'Terriskai: Terror of The Skies' is scheming to complete his evil plan to defeat the entire group of players for the ultimate victory.

The Legendary DXP digital game allows users to customize their gaming experience like never before. Players will now be able to select any one of five completely different match types: Solo play (play vs A.I.), VS Friends (play against your friends), Quick Match (randomly puts players together), Custom Match (allows users to configure matches) and The Gauntlet (allows for ongoing 5 player tournaments). In addition to having a chance to win exclusive in-game rewards through tournaments and weekly leagues in The Gauntlet, Legendary DXP will also offer players a wide variety of cosmetic enhancements via microtransactions.

"Expanding Upper Deck's award-winning table top games to the digital world opens the door to incredible new features and replayability that were never before possible," said Jason Masherah, President of Upper Deck. "The first digital launch of Legendary DXP gives our fans around the world an exciting insight of things to come."

"This is truly a defining moment for our studio and we couldn't have found a better company to work with than Upper Deck," said Brad Crayton, Chief Operating Office at SkyReacher.  "Legendary is such an iconic table top game and we are proud to have been selected as the development studio that is bringing the company's first game to the digital world."

Legendary DXP will officially release on August 17th in conjunction with Gen Con, the original and longest running game convention in the world. Players can download the new game starting on August 17th via the App Store. Fans can sign up now to gain free early access and learn more about the upcoming release of Legendary DXP and other Upper Deck games at www.PlayLegendaryDXP.com.

About Upper Deck
Upper Deck, headquartered in Carlsbad, Calif., is a worldwide sports and entertainment company built on the pillars of quality craftsmanship, authenticity and innovation with a dedication to creating products that turn memorable moments into collectibles. Upper Deck maintains an award winning portfolio of gaming, sports, entertainment products and collectibles.

About SkyReacher
Founded in 2010, SkyReacher is a leading game development studio creating content across mobile, desktop and web platforms. SkyReacher's team of passionate game industry veterans have worked on many AAA titles ranging from MMORPGs to real-time strategy games.

SkyReacher is dedicated to pushing the boundaries of game development by embracing new technologies in order to bring innovative game experiences to life.

Upper Deck Press Contact:
Name: Jodi Wasserman
Email: Jodi_Wasserman@UpperDeck.com 

Gen Con Press Contact: 
Name: Jake Theis
Email: Jake.Theis@gencon.com 

SOURCE Upper Deck

MAGNUM FC at the Chamber of Deputies for the 54th Academic Chamber of AEREC Meeting

ROME, June 22, 2017 /PRNewswire/ --

The 54th Academic Conference at AEREC, the prestigious European Academy for Economic and Cultural Relations led by the brilliant Ernesto Carpintieri, will be held tomorrow, Friday 23rd June 2017 at the Chamber of Deputies.

     (Photo: http://mma.prnewswire.com/media/526849/MAGNUM_Fight_Championship_2.jpg )

The conference theme is "Sport, wellness and health, new trends" and will discuss Contact Sports, which are a growing trend and increasingly popular in Italy, where athletes and fans make up over 6 million enthusiasts.

MAGNUM FC is the Italian and international sector leader for promoting Contact Sports after hosting only one event, thanks to its collaboration with the KUNLUN Fight, the largest Chinese media group, which enabled the broadcasting of the event on the CCTV television network.

Patrizia Marin, CEO of MAGNUM FC will speak at this highly prestigious institution, along with Massimiliano Baggio, Kombat League President; Michele Verginelli, World Champion of MMA and Brand Ambassador of MAGNUM FC; Prof. Vincenzo Russo, Scientific Director of the Master in Marketing and Communication of Sport at the IULM University of Milan; Adolfo Panfili, professor of medical affairs; and Antonella Salvucci, actress and television presenter.

"We, together with KUNLUN Fight MMA 14, invite you to MAGNUM FC 2 which will take place in Rome on Saturday, 22 July from 5pm onwards in the beautiful setting of the Church Palace, Via Aurelia 481. MAGNUM FC 2 features the most important Italian and international fighters, as well as a female match between the Italian Micol Di Segni and Anastasiya Gomostaeva of Ukraine," stated Max Baggio, Chairman of Kombat League and deus ex machina of MAGNUM FC.

Patrizia Marin, CEO of MAGNUM FC, said, "We are excited to be able to present MAGNUM FC to the Chamber of Deputies and we are pleased to announce that for the first time in Italy, Contact Sports will have a dedicated teaching space thanks to the Master in Marketing and Communication of Sport at the IULM University of Milan. Marco Polowill be part of the Faculty and will be responsible for Contact Sports."

MAGNUM FC 2's current Fight Card features international athletes including Lin Heqin, Lv Zhenhong, Song Yadong, Wu Haotian, Zhang Lipeng, Roberto Soldic, Zhang Meixuan, Yari Orsini, Lukasz Parobiec, Franco de Martiis, Ion Deal, Giancarlo Grasselli, Claudio Amoruso, Gabriele Imbesi, Victor Gangan, Edoardo Lorenzetti and Daniel Gheorcioiu.

After the success of March, Carlo Pedersoli Jr., Mauro Cerilli, Fabio Russo, Fabio Scaravilli, Marcin Lazarz, Hraco Darpinyan, Stjepan-Bekavac return to fight at MAGNUM FC.
The highlight of the all-female matches will see Micol Di Segni and Anastasiya Gomostaeva in the ring.

MAGNUM FC 2, the must-see championship event that you cannot afford to miss: Rome, July 22 at the Church Palace (https://www.diyticket.it/events/sport/429/magnum-fc).

Info & Media Relations :

Diana Patty Tonin/ press@magnumfc.org / +39-339-7621393
Martina Baratta/ martina@magnumfc.org / +39-333-9938072  

Jerry Kelly and Exact Sciences Team Up to Promote Colon Cancer Screening

Golfer launches multi-year, Cologuard®-branded campaign

MADISON, Wis., June 22, 2017 /PRNewswire/ -- Exact Sciences today announced it is teaming up with Madison professional golfer Jerry Kelly to help drive home the importance of colorectal cancer screening.  Beginning at this week's American Family Insurance Championship, Kelly will wear a Cologuard-branded hat for the next two years at tournaments around the country to help raise awareness of colon cancer and the importance of regular screening beginning at age 50 for individuals at average risk.

"We're joining with Jerry to remind people that turning 50 isn't just a milestone, it's a time to take control of your health," said Kevin Conroy, chairman and chief executive officer of Exact Sciences. "Together we'll be working to raise awareness about colon cancer, the urgent need for screening, and Cologuard as a noninvasive option that can be completed at home."

A longtime presence on tour, Kelly, who turned 50 in November 2016, is known for a blue-collar work ethic and grinder mentality befitting his Midwestern roots. A member of the 2003 Presidents Cup team, he has played in more than 600 tournaments, earning three wins, 91 top tens and 194 top 25 finishes. Kelly currently ranks 31st on the PGA Tour all-time money list, with career earnings of more than $28.8 million.

"Exact Sciences is a leader in early cancer detection and Cologuard is a breakthrough technology that's changed the way hundreds of thousands of Americans are getting screened for colon cancer," Kelly said. "It's exciting to join Exact Sciences in helping improve lives through cancer screening and awareness. I look forward to representing Cologuard and to encouraging people to talk to their doctor about colon cancer screening options that best fit their lifestyle."

Cologuard uses the DNA and blood protein found in a person's stool to detect biomarkers associated with colon cancer and precancerous growths. Once ordered by a doctor, a Cologuard box is delivered to a patient's home via UPS. The patient collects their sample at a convenient time and uses a prepaid shipping label to send the specimen to Exact Sciences' laboratories. Doctors receive test results within a few weeks. Cologuard is only available by prescription and individuals need to discuss their options with their doctor, as Cologuard is not for everyone.

Colon cancer is widely known as one of the most preventable, yet least prevented forms of cancer. It's the No. 2 cancer killer in the U.S., claiming 50,000 lives per year more than both breast cancer (41,000/year) and prostate cancer (26,000/year). Despite colorectal cancer's preventability, more than 35 million Americans age 50 and older are not current with screening guidelines.

About Cologuard
Cologuard was approved by the FDA in August 2014 and results from Exact Sciences' prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. Cologuard is included in the recommendations of the U.S. Preventive Services Task Force (2016) and the American Cancer Society's (2014) colorectal cancer screening guidelines. Stool DNA is included in the combined screening guidelines of the American Cancer Society / U.S. Multi-Society Task Force/American College of Radiology (2008), the American College of Gastroenterology guidelines (2009) and the National Comprehensive Cancer Network (2016). Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for colorectal cancer. Cologuard is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. False positives and false negatives do occur. Any positive test result should be followed by a diagnostic colonoscopy. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. For more information about Cologuard, visit www.cologuardtest.com. Rx Only.

About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences or find Exact Sciences on Facebook.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales and marketing efforts, expectations concerning payor reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payors to cover Cologuard and reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in healthcare pricing, coverage and reimbursement; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Report(s) on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:  Scott Larrivee, Exact Sciences, 608-535-8673, slarrivee@exactsciences.com

 

SOURCE EXACT SCIENCES CORP

Jerry Kelly and Exact Sciences Team Up to Promote Colon Cancer Screening

Golfer launches multi-year, Cologuard®-branded campaign

MADISON, Wis., June 22, 2017 /PRNewswire/ -- Exact Sciences today announced it is teaming up with Madison professional golfer Jerry Kelly to help drive home the importance of colorectal cancer screening.  Beginning at this week's American Family Insurance Championship, Kelly will wear a Cologuard-branded hat for the next two years at tournaments around the country to help raise awareness of colon cancer and the importance of regular screening beginning at age 50 for individuals at average risk.

"We're joining with Jerry to remind people that turning 50 isn't just a milestone, it's a time to take control of your health," said Kevin Conroy, chairman and chief executive officer of Exact Sciences. "Together we'll be working to raise awareness about colon cancer, the urgent need for screening, and Cologuard as a noninvasive option that can be completed at home."

A longtime presence on tour, Kelly, who turned 50 in November 2016, is known for a blue-collar work ethic and grinder mentality befitting his Midwestern roots. A member of the 2003 Presidents Cup team, he has played in more than 600 tournaments, earning three wins, 91 top tens and 194 top 25 finishes. Kelly currently ranks 31st on the PGA Tour all-time money list, with career earnings of more than $28.8 million.

"Exact Sciences is a leader in early cancer detection and Cologuard is a breakthrough technology that's changed the way hundreds of thousands of Americans are getting screened for colon cancer," Kelly said. "It's exciting to join Exact Sciences in helping improve lives through cancer screening and awareness. I look forward to representing Cologuard and to encouraging people to talk to their doctor about colon cancer screening options that best fit their lifestyle."

Cologuard uses the DNA and blood protein found in a person's stool to detect biomarkers associated with colon cancer and precancerous growths. Once ordered by a doctor, a Cologuard box is delivered to a patient's home via UPS. The patient collects their sample at a convenient time and uses a prepaid shipping label to send the specimen to Exact Sciences' laboratories. Doctors receive test results within a few weeks. Cologuard is only available by prescription and individuals need to discuss their options with their doctor, as Cologuard is not for everyone.

Colon cancer is widely known as one of the most preventable, yet least prevented forms of cancer. It's the No. 2 cancer killer in the U.S., claiming 50,000 lives per year more than both breast cancer (41,000/year) and prostate cancer (26,000/year). Despite colorectal cancer's preventability, more than 35 million Americans age 50 and older are not current with screening guidelines.

About Cologuard
Cologuard was approved by the FDA in August 2014 and results from Exact Sciences' prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. Cologuard is included in the recommendations of the U.S. Preventive Services Task Force (2016) and the American Cancer Society's (2014) colorectal cancer screening guidelines. Stool DNA is included in the combined screening guidelines of the American Cancer Society / U.S. Multi-Society Task Force/American College of Radiology (2008), the American College of Gastroenterology guidelines (2009) and the National Comprehensive Cancer Network (2016). Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for colorectal cancer. Cologuard is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. False positives and false negatives do occur. Any positive test result should be followed by a diagnostic colonoscopy. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. For more information about Cologuard, visit www.cologuardtest.com. Rx Only.

About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences or find Exact Sciences on Facebook.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales and marketing efforts, expectations concerning payor reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payors to cover Cologuard and reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in healthcare pricing, coverage and reimbursement; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Report(s) on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:  Scott Larrivee, Exact Sciences, 608-535-8673, slarrivee@exactsciences.com

 

SOURCE EXACT SCIENCES CORP